Reduced Risk of Hypercalcemia for Hemodialysis Patients by Administering Calcitriol at Night
- 1 May 1992
- journal article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 19 (5), 460-464
- https://doi.org/10.1016/s0272-6386(12)80955-3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Calcium Acetate Control of Serum Phosphorus in Hemodialysis PatientsAmerican Journal of Kidney Diseases, 1991
- The Treatment of Uraemic Hyperphosphataemia with Calcium Acetate and Calcium Carbonate: A Comparative StudyNephrology Dialysis Transplantation, 1991
- Low Calcium Dialysate and High-Dose Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Haemodialysis PatientsNephrology Dialysis Transplantation, 1990
- Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolismKidney International, 1989
- Calcium acetate, an effective phosphorus binder in patients with renal failureKidney International, 1989
- The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.JCI Insight, 1989
- The Effect of Dialysate Calcium Levels on Blood Pressure During HemodialysisAmerican Journal of Kidney Diseases, 1986
- Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing DialysisNew England Journal of Medicine, 1986
- Increased Ionized Calcium and Left Ventricular Contractility during HemodialysisNew England Journal of Medicine, 1984